Roger M Lane

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. ncbi request reprint Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease
    Roger M Lane
    Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
    J Lipid Res 46:949-68. 2005
  2. doi request reprint Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE epsilon 4, and hyperhomocysteinemia in neurodegenerative dementias
    Roger M Lane
    Novartis Neuroscience, Novartis Pharmaceuticals Corporation, 59 Route 10, East Hanover, NJ 07936 1080, USA
    Med Hypotheses 73:230-50. 2009
  3. ncbi request reprint Acetylcholinesterase and its inhibition in Alzheimer disease
    Roger M Lane
    Novartis Neuroscience, Novartis Pharmaceuticals Corp, East Hanover, NJ 07936 1080, USA
    Clin Neuropharmacol 27:141-9. 2004
  4. ncbi request reprint Targeting acetylcholinesterase and butyrylcholinesterase in dementia
    Roger M Lane
    Novartis Neuroscience, Novartis Pharmaceuticals Corporation, NJ, USA
    Int J Neuropsychopharmacol 9:101-24. 2006
  5. ncbi request reprint Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences
    Murat Emre
    Department of Neurology, Istanbul Faculty of Medicine, Istanbul, Turkey
    J Alzheimers Dis 11:509-19. 2007

Detail Information

Publications5

  1. ncbi request reprint Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease
    Roger M Lane
    Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
    J Lipid Res 46:949-68. 2005
    ..This review examines the current evidence for diet, lipid homeostasis, and apoE in the pathogenesis of AD. Effects on the cholinergic system and response to cholinesterase inhibitors by APOE allele carrier status are discussed briefly...
  2. doi request reprint Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE epsilon 4, and hyperhomocysteinemia in neurodegenerative dementias
    Roger M Lane
    Novartis Neuroscience, Novartis Pharmaceuticals Corporation, 59 Route 10, East Hanover, NJ 07936 1080, USA
    Med Hypotheses 73:230-50. 2009
    ....
  3. ncbi request reprint Acetylcholinesterase and its inhibition in Alzheimer disease
    Roger M Lane
    Novartis Neuroscience, Novartis Pharmaceuticals Corp, East Hanover, NJ 07936 1080, USA
    Clin Neuropharmacol 27:141-9. 2004
    ..If such differences between ChE-Is are shown to have clinical correlates, this may prompt reconsideration of the rationale and expectations of some agents in the long-term management of AD...
  4. ncbi request reprint Targeting acetylcholinesterase and butyrylcholinesterase in dementia
    Roger M Lane
    Novartis Neuroscience, Novartis Pharmaceuticals Corporation, NJ, USA
    Int J Neuropsychopharmacol 9:101-24. 2006
    ....
  5. ncbi request reprint Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences
    Murat Emre
    Department of Neurology, Istanbul Faculty of Medicine, Istanbul, Turkey
    J Alzheimers Dis 11:509-19. 2007
    ..In both populations, hallucinations may identify patients who are likely to be more treatment-responsive...